David Rosmarin, EADV 2021: Efficacy and Safety of Ruxolitinib Cream in Vitiligo
Dr David Rosmarin (Tufts Medical Center, Boston, MA, USA) kindly took the time to speak with touchIMMUNOLOGY about the results from the safety and efficacy studies investigating ruxolitinib cream in vitiligo.
His presentation entitled ‘Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
Questions
- Could you tell us a little about the aims and design of the Phase 3 TRuE-V program?
- What have we learned so far from the 24-week data?
- What is the clinical significance of these findings?
- Which patients are likely to benefit most from ruxolitinib cream and in whom is it contraindicated?
- What will be the next steps towards regulatory approval for ruxolitinib cream in the treatment of vitiligo?
Disclosures: Dr David Rosmarin has received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; has received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals Inc; and has served as a paid speaker for AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
